125I粒子植入治疗进展期非小细胞肺癌的临床效果及对患者CEA、CYFRA21-1水平分析

摘要

目的 分析进展期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者行125I粒子植入治疗后的临床效果及其癌胚抗原(carcino-embryonic antigen,CEA)、细胞角蛋白19片段(cytokeratin-19-fragment,CYFRA21-1)水平变化.方法 选取2014年1月至2015年7月本院接诊的进展期NSCLC患者58例为研究对象,将其中采取常规化疗的患者29例纳入对照组,采取125I粒子植入治疗的患者29例纳入观察组,比较两组患者的近期疗效、肿瘤标志物水平及肺功能.结果 观察组患者肿瘤总体控制率显著高于对照组(P<0.05).治疗后,两组患者CEA、CYFRA21-1、糖类抗原125水平均显著降低(P<0.05),且观察组患者上述指标水平均显著低于对照组(P<0.05).治疗后,两组患者的用力肺活量和第一秒用力呼气量均有所上升,观察组患者各指标对比差异均有显著性(P<0.05),对照组患者各指标比较均无显著差异(P>0.05);两组间对比均无显著差异(P>0.05).结论 125I粒子植入治疗进展期NSCLC,能提高肿瘤的总体控制率,改善肺功能.%Objective To analyze the clinical efficacy of 125I particle implantation in advanced non-small cell lung cancer (NSCLC) and the changes of carcino-embryonic antigen (CEA) and cytokeratin-19-fragment (CYFRA21-1) levels. Method From January 2014 to July 2015, 58 patients with NSCLC in our hospital were selected, 29 patients underwent routine chemotherapy were included into control group, 29 patients underwent 125I particle implantation were included into observation group, the recent efficacy, tumor marker levels, lung function were compared between the two groups. Result The overall control rate in observation group was higher than that of control group (P<0.05). After treatment, the levels of CEA, CYFRA21-1, CA125 in two groups were reduced (P < 0.05), and the above indexes in observation group were lower than control group (P < 0.05). After treatment, the forced vital capacity and forced expiratory volume in first second of the two groups were increased. There were significant differences of the indexes in observation group (P<0.05). But there were no significant differences in control group (P>0.05). There were no significant differences between the two groups (P>0.05). Conclusion 125I particle implantation in advanced NSCLC patients can increase the control rate of cancer focus, improve lung function.